Search research articles
Contact Us
Filters
Showing results (41-50 of 47) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 47 results.
American Journal of Human Genetics
|
December 31, 2005
Functional variant in a bitter-taste receptor (hTAS2R16) influences risk of alcohol dependence
Anthony L Hinrichs, Jen C Wang, Bernd Bufe, et al.
Nature Medicine
|
June 17, 2022
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, et al.
Nature Medicine
|
June 17, 2022
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
May 13, 2016
Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State
Melissa P Wasserstein, Mary Andriola, Georgianne Arnold, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
January 23, 2016
Newborn screening for Krabbe disease in New York State: the first eight years' experience
Joseph J Orsini, Denise M Kay, Carlos A Saavedra-Matiz, et al.
The Lancet. Neurology
|
March 20, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
John W Day, Richard S Finkel, Claudia A Chiriboga, et al.
Pediatric Neurology
|
March 24, 2009
Newborn screening for Krabbe disease: the New York State model
Patricia K Duffner, Michele Caggana, Joseph J Orsini, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 47) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 47 results.
American Journal of Human Genetics
|
December 31, 2005
Functional variant in a bitter-taste receptor (hTAS2R16) influences risk of alcohol dependence
Anthony L Hinrichs, Jen C Wang, Bernd Bufe, et al.
Nature Medicine
|
June 17, 2022
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, et al.
Nature Medicine
|
June 17, 2022
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
May 13, 2016
Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State
Melissa P Wasserstein, Mary Andriola, Georgianne Arnold, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
January 23, 2016
Newborn screening for Krabbe disease in New York State: the first eight years' experience
Joseph J Orsini, Denise M Kay, Carlos A Saavedra-Matiz, et al.
The Lancet. Neurology
|
March 20, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
John W Day, Richard S Finkel, Claudia A Chiriboga, et al.
Pediatric Neurology
|
March 24, 2009
Newborn screening for Krabbe disease: the New York State model
Patricia K Duffner, Michele Caggana, Joseph J Orsini, et al.
Page
of 5